title: Physical training and metabolic supplementation reduce spontaneous atherosclerotic plaque rupture and prolong survival in hypercholesterolemic mice.
abstract: Moderate physical exercise (PE) combined with metabolic treatment (MT) (antioxidants and l-arginine) are well known to reduce atherosclerotic lesion formation in hypercholesterolemic mice. However, the long-term beneficial effects on unstable atheroma remain poorly understood. We started early PE training in large groups of 6-week-old hypercholesterolemic mice (by graduated swimming) alone or in combination with nutritional supplementation (1.0% vitamin E added to the chow and 0.05% vitamin C and 6% l-arginine added to the drinking water). Inactive controls did not receive PE. The spontaneous development of atherosclerotic plaque rupture (associated with advanced atherosclerosis) and survival rates were evaluated. Moderate PE elicited an increase in plasma levels of nitric oxide. Early combined treatment with PE and MT in the hypercholesterolemic mice significantly reduced lesions (also detected noninvasively at 10 months) and spontaneous atherosclerotic plaque rupture and prolonged survival more effectively than each intervention alone. Thus, early concerted actions of MT and PE improve the natural history of atherosclerotic lesions and reduce the plaque instability in hypercholesterolemic mice.
authors.affiliation: *Department of General Pathology, Division of Clinical Pathology, Excellence Research Center on Cardiovascular Diseases, and claunap@tin.it lignarro@mednet.ucla.edu.|Whitaker Cardiovascular Institute, Boston University, Boston, MA 02118.|Research Center on Craniofacial Malformations-MRI, School of Medicine, Second University of Naples, Naples 80138, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Napoli
authors.affiliation: Division of Anesthesiology and.
authors.forename: Sharon
authors.initials: S
authors.lastname: Williams-Ignarro
authors.affiliation: *Department of General Pathology, Division of Clinical Pathology, Excellence Research Center on Cardiovascular Diseases, and.
authors.forename: Filomena
authors.initials: F
authors.lastname: de Nigris
authors.affiliation: Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55905.
authors.forename: Lilach O
authors.initials: LO
authors.lastname: Lerman
authors.affiliation: **Department of Biomorphological Sciences, University of Naples Federico II, Naples 80131, Italy.
authors.forename: Francesco P
authors.initials: FP
authors.lastname: D'Armiento
authors.affiliation: Department of Internal Medicine, Berkshire Medical Center, Pittsfield, MA 01201; and.
authors.forename: Ettore
authors.initials: E
authors.lastname: Crimi
authors.affiliation: Department of Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735.
authors.forename: Russell E
authors.initials: RE
authors.lastname: Byrns
authors.affiliation: *Department of General Pathology, Division of Clinical Pathology, Excellence Research Center on Cardiovascular Diseases, and.
authors.forename: Amelia
authors.initials: A
authors.lastname: Casamassimi
authors.affiliation: Research Center on Craniofacial Malformations-MRI, School of Medicine, Second University of Naples, Naples 80138, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lanza
authors.affiliation: Research Center on Craniofacial Malformations-MRI, School of Medicine, Second University of Naples, Naples 80138, Italy.
authors.forename: Fernando
authors.initials: F
authors.lastname: Gombos
authors.affiliation: *Department of General Pathology, Division of Clinical Pathology, Excellence Research Center on Cardiovascular Diseases, and.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Sica
authors.affiliation: Department of Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735 claunap@tin.it lignarro@mednet.ucla.edu.
authors.forename: Louis J
authors.initials: LJ
authors.lastname: Ignarro
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000151:congenital / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control*; D019587:Dietary Supplements; D018450:Disease Progression; D016166:Free Radical Scavengers / Q000378:metabolism; D006937:Hypercholesterolemia / Q000150:complications / Q000201:enzymology / Q000473:pathology*; D018810:Magnetic Resonance Angiography; D051379:Mice; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010805:Physical Conditioning, Animal / Q000502:physiology*; D015996:Survival Rate
chemical_list: D016166:Free Radical Scavengers; D052250:Nitric Oxide Synthase Type III